UNSPSC 51183510: Metformin hydrochloride

This classification denotes an anti-diabetic agent with the molecular formula C4H11N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 786Z46389E, chemically known as 1,1-dimethylbiguanide but more generally known as metformin hydrochloride, which bears US NIH Compound Identifier 4091. European Medicines Agency schedules Metformin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03200MIG.

Most nations, for tariff and trade purposes, schedule metformin hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, METFORMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metformin hydrochloride bears US NLM identifiers UMLS ID C0770893 and NCI Concept Code C29251. SMILES: CN(C)C(=N)NC(=N)N.CL.

UNSPSC 51183510 Metformin hydrochloride is a Commodity code tracking generic pharmaceutical products supplied to state and local government health facilities and programs through cooperative purchasing agreements. The work involves manufacturing and supply of metformin hydrochloride and related generic multi-source pharmaceuticals meeting FDA and cGMP standards, with vendors distributing products through authorized pharmaceutical wholesalers to participating state agencies, local health departments, and subordinate government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body sourcing under this code; MMCAP coordinates procurement across participating jurisdictions including Minnesota and Oregon, with resulting contracts serving multiple state and local government entities simultaneously. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), possess current cGMP certification and Drug Supply Chain Security Act (DSCSA) compliance, and provide detailed product data including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing locations. Pricing structures include flat price, net price formats (NF30, NF60, NF90), or WAC-minus options, with vendors subject to a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.

MMCAP's Request for Proposal S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, represents the most recent significant activity under this code. The RFP evaluates submissions on price competitiveness (75 percent weight), fixed pricing (10 percent), compliance with administrative data format and EDI capability (5 percent each), and agreement to the 3 percent administrative fee (5 percent). Awarded vendors will supply products through authorized wholesalers by July 1, 2026, under a two-year initial contract term with optional extensions at MMCAP's discretion. Vendors must maintain comprehensive insurance including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability, and all products must carry expiration dates at least one year from manufacture with a minimum six-month shelf life. No specific set-aside designations or dollar values were disclosed in the available solicitation documentation.